- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Growing Burden of Chronic Kidney Disease in the US
Awareness of chronic kidney disease remains low in the United States, yet the prevalence of the disease will rise over the next 15 years, according to a model developed by RTI.
Awareness of chronic kidney disease (CKD) remains low in the United States, yet the prevalence of the disease will rise over the next 15 years, according to a model developed by RTI.
The findings, published in the American Journal of Kidney Diseases, estimate that the number of adults age 30 years or older with CKD will increase from the current level of 13.2% to 16.7% in 2030.
"We were surprised by the high probability of developing CKD during a lifetime," Thomas Hoerger, PhD, health economist and senior fellow at RTI and the paper's lead author, said in a statement. "It's higher than most diseases that immediately jump to mind, and while the likelihood of chronic kidney disease progressing to complete kidney failure is much lower, CKD itself has been linked to a number of comorbidities and adverse health outcomes."
With residual lifetime incidence of CKD for adults aged 30-49 years, 50-64 years, and 65 years and older with no CKD at baseline is 54%, 52%, and 42%, respectively, which is higher than lifetime incidences of breast cancer in woman (12.5%) and diabetes (33%-38%), according to investigators.
Dr Hoerger hopes that the model developed by RTI will make policy makers aware of the growing issue of CKD. During the next several decades it is likely that nearly 10% of adults aged 30 to 64 years will develop stage 4 CKD and more than 3% will develop kidney failure.
The authors also found that as the prevalence of CKD rises, the impact will be felt not just by individual patients, but by the health system as a whole. In 2012, Medicare expenditures for kidney disease and kidney failure were already more than $87 million.
“From a national burden perspective, we estimate that the population prevalence of CKD will increase in coming decades, suggesting that development of interventions to slow CKD onset and progression should be considered,” the authors concluded.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
